LIV Body itself does not prescribe - licensed providers through OpenLoop Healthcare Partners, PC make all clinical decisions independently
Investigators shared new data on retatrutide, an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)/glucagon (GCG) receptor agonist, and its effects on obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH)
Studies show that stopping the medication can sometimes, but not always, cause a persons weight to creep back up, along with blood pressure, blood sugar and cholesterol levels
Second, the practical mechanics of reconstitution, dose calculation, and injection technique are unchanged by the new data, but they matter more now